Eli Lilly and Company (LLY)vsSurrozen Inc (SRZN)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
SRZN
Surrozen Inc
$19.00
-2.31%
HEALTHCARE · Cap: $228.61M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 691986% more annual revenue ($79.67B vs $11.51M). LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SRZN
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-53.6%
Fair Value
$16.01
Current Price
$19.00
$2.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Revenue surging 408.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -62.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : SRZN
The strongest argument for SRZN centers on Revenue Growth, Debt/Equity. Revenue growth of 408.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : SRZN
The primary concerns for SRZN are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while SRZN is a hypergrowth play — different risk/reward profiles.
SRZN carries more volatility with a beta of 0.56 — expect wider price swings.
SRZN is growing revenue faster at 408.6% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 32/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Surrozen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform, which is designed to modulate targeted immune responses. The company's promising pipeline includes novel antibody therapeutics aimed at treating serious oncological and autoimmune disorders, addressing critical unmet medical needs. With a strong focus on research and development, coupled with strategic partnerships, Surrozen is well-positioned to deliver transformative therapies, offering significant potential for growth and a meaningful impact within the biopharmaceutical landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?